Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gentamicin, genetic variation and deafness in preterm children.

BMC pediatrics - 5 Mar 2014

Bitner-Glindzicz Maria, Rahman Shamima, Chant Kathy, Marlow Neil

Abstract excerpt

BACKGROUND: Hearing loss in children born before 32 weeks of gestation is more prevalent than in full term infants. Aminoglycoside antibiotics are routinely used to treat bacterial infections in babies on neonatal intensive care units. However, this type of medication can have harmful effects on the auditory system. In order to avoid this blood levels should be maintained in the therapeutic range. However in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Case-Control Studies
Share to Deafness

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Gentamicins

Share to Infant, Newborn

Share to Infant, Premature, Diseases

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 24593698
DOI: 10.1186/1471-2431-14-66
PMCID: PMC3984755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gentamicin, genetic variation and deafness in preterm children.PMID 24593698Read ↗

Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants.Semantic proximity Read ↗

Non-invasive Prenatal MT-RNR1 Pharmacogenetic Testing for the Prevention of Aminoglycoside-Induced Profound Hearing LossSemantic proximity Read ↗

Genetic testing in the acute setting: a round table discussion.Semantic proximity Read ↗

The future role of genetic screening to detect newborns at risk of childhood-onset hearing loss.Semantic proximity Read ↗

Defining the cellular and molecular mechanism of maternally inherited hearing lossSemantic proximity Read ↗

A cohort study of neonatal hearing testing and genetic screening for variants associated with susceptibility to aminoglycoside antibiotic-induced hearing loss in Beijing, China.Semantic proximity Read ↗

Maternally inherited hearing impairment.Semantic proximity Read ↗

Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis.Semantic proximity Read ↗

Is deafness mutation screening required in cystic fibrosis patients?Semantic proximity Read ↗

Screening of the mitochondrial A1555G mutation in patients with sensorineural hearing loss.Semantic proximity Read ↗

A maternal hereditary deafness pedigree of the A1555G mitochondrial mutation, causing aminoglycoside ototoxicity predisposition.Semantic proximity Read ↗

Detecting mitochondrial mutations associated with aminoglycoside ototoxicity by noninvasive prenatal testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.